Tag: USFDA
Once-weekly Altuviiio, a new kind of factor VIII therapy for haemophilia A that provides considerable bleed prevention, has been approved by the US FDA.
Altuviiio [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], formerly known as efanesoctocog alfa, is a first-in-class, highly sustained factor…
